+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Vincristine"

From
From
Hypereosinophilic Syndrome - Pipeline Insight, 2024 - Product Thumbnail Image

Hypereosinophilic Syndrome - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
From
From
Investigation Report on China's Pegaspargase Market, 2019-2023 - Product Thumbnail Image

Investigation Report on China's Pegaspargase Market, 2019-2023

  • Report
  • September 2019
  • 30 Pages
  • China
From
Imbruvica - Product Thumbnail Image

Imbruvica

  • Report
  • January 2019
  • 51 Pages
  • Global
From
From
From
From
  • 14 Results (Page 1 of 1)
Loading Indicator

Vincristine is a chemotherapy drug used to treat a variety of leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). It is a type of vinca alkaloid, derived from the Madagascar periwinkle plant, and works by inhibiting the growth of cancer cells. Vincristine is typically administered intravenously, and is often used in combination with other drugs to maximize its effectiveness. Vincristine is a widely used drug in the treatment of leukemias, and is often prescribed in combination with other drugs. It is generally well-tolerated, with few side effects. However, it can cause peripheral neuropathy, which can lead to numbness and tingling in the hands and feet. The vincristine market is highly competitive, with many companies offering generic versions of the drug. Some of the major players in the market include Pfizer, Novartis, Teva Pharmaceuticals, Mylan, and Sun Pharmaceuticals. Show Less Read more